Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seviteronel - Innocrin Pharmaceuticals

Next Previous
Drug Profile

Seviteronel - Innocrin Pharmaceuticals

Alternative Names: INO-464; VT-464

Latest Information Update: 18 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Innocrin Pharmaceuticals
  • Class Antiandrogens; Antineoplastics; Fluorine compounds; Naphthalenes; Propanols; Small molecules; Triazoles
  • Mechanism of Action Androgen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer; Solid tumours
  • Phase I/II Triple negative breast cancer

Most Recent Events

  • 31 May 2024 Efficacy and adverse event data from the phase Ib/II 4CAST trial in Triple negative breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 01 Jul 2022 Phase-I/II clinical trials in Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in Australia (PO) (NCT04947189)
  • 01 Jul 2022 Preclinical trials in Triple-negative-breast-cancer (Combination therapy) in Australia (PO) prior to July 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top